K Junker

Summary

Affiliation: Friedrich Schiller University
Country: Germany

Publications

  1. doi [Therapy selection in patients with advanced bladder cancer. Is molecular biology helpful?]
    K Junker
    Klinik für Urologie, Universitatsklinikum Jena, Lessingstraße 1, 07743 Jena
    Urologe A 51:805-12. 2012
  2. pmc Sporadic renal cell carcinoma in young and elderly patients: are there different clinicopathological features and disease specific survival rates?
    Stefan Denzinger
    Department of Urology, University of Regensburg, Regensburg, Germany
    World J Surg Oncol 5:16. 2007
  3. pmc Comparative proteomic analysis of normal and tumor stromal cells by tissue on chip based mass spectrometry (toc-MS)
    Niko Escher
    Core Unit Chip Application, Institute of Human Genetics, University Hospital Jena, Jena, Germany
    Diagn Pathol 5:10. 2010
  4. doi [Securing the future through research - light on the horizon?]
    K Junker
    Klinik für Urologie, Universitatsklinikum Jena, Friedrich Schiller Universitat, Lessingstraße 1, 07743 Jena, Deutschland
    Urologe A 50:932-7. 2011
  5. ncbi Genetic characterization of lung metastases in renal cell carcinoma
    Kerstin Junker
    Department of Urology, Friedrich Schiller University, Lessingstrasse 1, 07743 Jena, Germany
    Oncol Rep 10:1035-8. 2003
  6. ncbi CD70: a new tumor specific biomarker for renal cell carcinoma
    Kerstin Junker
    Department of Urology, Institute of Human Genetics and Anthropology, Friedrich Schiller University, Jena, Germany
    J Urol 173:2150-3. 2005
  7. ncbi Molecular clonal analysis of recurrent bladder cancer
    Kerstin Junker
    Department of Urology, Lessingstr 1, D 07743 Jena, Germany
    Oncol Rep 14:319-23. 2005
  8. ncbi Identification of protein pattern in kidney cancer using ProteinChip arrays and bioinformatics
    Kerstin Junker
    Department of Urology, Friedrich Schiller University, D 07743 Jena, Germany
    Int J Mol Med 15:285-90. 2005
  9. ncbi [Identification of biomarkers and therapeutic targets for renal cell cancer using ProteinChip technology]
    K Junker
    Klinik für Urologie, Universitätsklinik der FSU, Jena
    Urologe A 45:305-6, 308, 310-12 passim. 2006
  10. ncbi Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer
    K Junker
    Department of Urology, Friedrich Schiller University, Jena, Germany
    Cytogenet Genome Res 114:279-83. 2006

Detail Information

Publications67

  1. doi [Therapy selection in patients with advanced bladder cancer. Is molecular biology helpful?]
    K Junker
    Klinik für Urologie, Universitatsklinikum Jena, Lessingstraße 1, 07743 Jena
    Urologe A 51:805-12. 2012
    ..This paper gives an overview concerning the role of molecular biology for therapy decision-making...
  2. pmc Sporadic renal cell carcinoma in young and elderly patients: are there different clinicopathological features and disease specific survival rates?
    Stefan Denzinger
    Department of Urology, University of Regensburg, Regensburg, Germany
    World J Surg Oncol 5:16. 2007
    ..In the present retrospective study we reviewed clinicopathological features and disease specific survival rates in young patients (<= 45 years) with RCC and compared them to old patients (>= 75 years) with RCC...
  3. pmc Comparative proteomic analysis of normal and tumor stromal cells by tissue on chip based mass spectrometry (toc-MS)
    Niko Escher
    Core Unit Chip Application, Institute of Human Genetics, University Hospital Jena, Jena, Germany
    Diagn Pathol 5:10. 2010
    ..The newly described toc-MS technology allows an initial insight into proteomic differences between small numbers of exactly defined cells from normal and tumor stroma...
  4. doi [Securing the future through research - light on the horizon?]
    K Junker
    Klinik für Urologie, Universitatsklinikum Jena, Friedrich Schiller Universitat, Lessingstraße 1, 07743 Jena, Deutschland
    Urologe A 50:932-7. 2011
    ..As a result, research must be an essential part of our specialty on the one hand and the results of research must be applied to the whole extent of urology on the other hand...
  5. ncbi Genetic characterization of lung metastases in renal cell carcinoma
    Kerstin Junker
    Department of Urology, Friedrich Schiller University, Lessingstrasse 1, 07743 Jena, Germany
    Oncol Rep 10:1035-8. 2003
    ..This study demonstrates, that lung metastases from renal cell carcinoma are characterized by an accumulation of specific genetic alterations which show a clonal relationship to the related primary tumors...
  6. ncbi CD70: a new tumor specific biomarker for renal cell carcinoma
    Kerstin Junker
    Department of Urology, Institute of Human Genetics and Anthropology, Friedrich Schiller University, Jena, Germany
    J Urol 173:2150-3. 2005
    ..To our knowledge the function of CD70 in solid tumors is not known. In the current study we analyzed CD70 protein expression in different RCC subtypes...
  7. ncbi Molecular clonal analysis of recurrent bladder cancer
    Kerstin Junker
    Department of Urology, Lessingstr 1, D 07743 Jena, Germany
    Oncol Rep 14:319-23. 2005
    ..These data indicate that recurrence is caused by cell dissemination from the original tumor. For that reason, an early instillation therapy should be performed after transurethral resection...
  8. ncbi Identification of protein pattern in kidney cancer using ProteinChip arrays and bioinformatics
    Kerstin Junker
    Department of Urology, Friedrich Schiller University, D 07743 Jena, Germany
    Int J Mol Med 15:285-90. 2005
    ..The ProteinChip System represents a key technology for the rapid detection of cancer specific proteomic patterns. It is possible to identify clear cell renal cancer with high sensitivity and specificity from minimal amounts of cells...
  9. ncbi [Identification of biomarkers and therapeutic targets for renal cell cancer using ProteinChip technology]
    K Junker
    Klinik für Urologie, Universitätsklinik der FSU, Jena
    Urologe A 45:305-6, 308, 310-12 passim. 2006
    ..This review presents the first results for renal cancer...
  10. ncbi Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer
    K Junker
    Department of Urology, Friedrich Schiller University, Jena, Germany
    Cytogenet Genome Res 114:279-83. 2006
    ..FISH can detect recurrence earlier than other methods like cytology, cystoscopy or biopsy histological examination...
  11. ncbi [Definition of specific protein patterns for advanced (metastatic) urinary bladder tumors for individual prognosis determination and treatment choice]
    K Junker
    Klinik für Urologie, Friedrich Schiller Universitat, Lessingstrasse 1, 07740 Jena
    Urologe A 46:1288. 2007
  12. doi [The German Renal Cell Tumor Network]
    K Junker
    Klinik für Urologie, Universitatsklinikum, Jena, Deutschland
    Urologe A 47:1171-2. 2008
    ..It is thus now possible to analyze more than 500 well-characterized tumor samples using different techniques...
  13. doi [Molecular characterization of metastatic renal cell carcinomas. Differentiation of prognosis and therapy]
    K Junker
    Klinik für Urologie, Universitatsklinikum, Jena, Deutschland
    Urologe A 47:1187-9. 2008
    ..Therefore, it is necessary to select the best therapy for each patient and to detect therapy resistance very early. Biomarkers in tumor tissue and serum were found correlating with therapy response...
  14. doi [Tumor profiling of renal cell tumors: relevance for diagnostics and therapy]
    K Junker
    Klinik für Urologie, Universitatsklinikum Jena, Jena, Deutschland
    Pathologe 30:105-10. 2009
    ..Therefore, it is necessary to select the best therapy for each patient and to detect therapy resistance very early. Biomarkers in tumor tissue and serum were found to correlate with therapy response...
  15. ncbi [Molecular diagnostics of renal diseases with underlying genetic predisposition]
    K Junker
    Molekularbiologisches Labor, Klinik für Urologie, FSU, Jena
    Urologe A 42:624-33. 2003
    ..However, it is necessary to evaluate in each individual case whether genetic diagnostics are reasonable. This will be discussed for polycystic renal diseases, agenesis and dysplasia of the kidney, and hereditary kidney tumors...
  16. pmc Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations
    Kerstin Junker
    Department of Urology, Friedrich Schiller University, Jena, Germany
    Neoplasia 10:1-7. 2008
    ..Therefore, FGFR3 represents a valuable prognostic marker of tumors with low malignant potential and can be used as surrogate marker for the detection of genetically stable bladder tumors...
  17. ncbi Familial and sporadic renal oncocytomas--a comparative molecular-genetic analysis
    K Junker
    Department of Urology, Jena, Germany
    Eur Urol 40:330-6. 2001
    ..Genetic causes of sporadic and familial renal oncocytomas are not known. We analyzed these tumors genetically in order to detect tumor-specific chromosome alterations...
  18. ncbi Genetic alterations in metastatic renal cell carcinoma detected by comparative genomic hybridization: correlation with clinical and histological data
    K Junker
    Department of Urology, D 07743 Jena, Germany
    Int J Oncol 17:903-8. 2000
    ..In conclusion, we identified genetic alterations associated with metastatic disease in RCC which could be useful for predicting prognosis. Genetic changes leading to metastases occurred early in tumorigenesis of metastatic tumors...
  19. ncbi Molecular genetic evaluation of fluorescence diagnosis in bladder cancer
    Kerstin Junker
    Department of Urology, Friedrich Schiller University, D 07743 Jena, Germany
    Int J Oncol 20:647-53. 2002
    ..The clinical importance of fluorescence diagnosis and the possible reduction of the recurrence rate have to be shown in ongoing clinical studies...
  20. ncbi Determination of telomerase activity for differential analysis of multifocal renal cell carcinomas
    W Fiedler
    Institute of Human Genetics and Anthropology, Department of Urology, Friedrich Schiller University Jena, Germany
    Kidney Int 56:1286-8. 1999
    ....
  21. ncbi [German Renal Cell Tumors Network]
    K Junker
    Klinik für Urologie, Friedrich Schiller Universitat, Lessingstrasse 1, 07743 Jena
    Urologe A 46:1166. 2007
  22. ncbi [Identification of rejection markers after kidney transplantation using protein chip technology]
    O Reichelt
    Klinik und Poliklinik für Urologie der FSU, Universitat, Lessingstrasse 1, 07740 Jena
    Urologe A 46:1161. 2007
  23. ncbi Elevated plasma TGF-beta1 in renal diseases: cause or consequence?
    U Junker
    Institute of Clinical Immunology, Friedrich Schiller University, Jena, Germany
    Cytokine 12:1084-91. 2000
    ..It is tempting to speculate that chronic elevation of TGF-beta1 in these patients may be critically involved in these conditions predisposing to renal cancer...
  24. ncbi Prognostic significance of mutations in the p53 gene in superficial bladder cancer
    R Dahse
    Klinikum der FSU Jena, Institut fur Humangenetik, 07740 Jena, Germany
    Oncol Rep 7:931-6. 2000
    ..Detectable p53 damage might be related to a more aggressive phenotype and a higher recurrence risk. Our results are discussed in the context of other studies reviewed from 1995-2000...
  25. ncbi ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients
    J Mueller
    Department of Urology, Friedrich Schiller University Jena, Lessingstrasse 1, D 07743 Jena, Germany
    Eur Urol 47:885-93; discussion 893-4. 2005
    ....
  26. ncbi Malignant behaviour of incidentally found small renal cell carcinomas in renal graft donors and recipients
    H Wunderlich
    Department of Urology, Friedrich Schiller University, Jena, Germany
    Transplant Proc 34:2224. 2002
  27. ncbi Mass spectrometry meets chip technology: a new proteomic tool in cancer research?
    F von Eggeling
    Institut fur Humangenetik und Anthropologie, Friedrich Schiller Universitat, Jena, Germany
    Electrophoresis 22:2898-902. 2001
    ..By applying this fast and powerful ProteinChip array technology it becomes possible to investigate complex changes at the protein level in cancer associated with tumor development and progression...
  28. doi [Educational initiative of the German Society of Urology for innovative research : Workshops 2009]
    K D Sievert
    Klinik für Urologie, Eberhards Karl Universität Tübingen, Hoppe Seyler Strasse 3, 72076, Tubingen, Deutschland
    Urologe A 49:91-4. 2010
    ..Accomplishing these objectives seems urgently necessary to preserve the interests of urologists, because more than ever research has become indispensable in an increasingly difficult environment of health care policy...
  29. ncbi Tissue-specific microdissection coupled with ProteinChip array technologies: applications in cancer research
    F von Eggeling
    Institute of Human Genetics and Anthropology, Jena, Germany
    Biotechniques 29:1066-70. 2000
    ..In particular, comparisons of the protein expression patterns from microdissected normal and tumor tissues indicated several differences, highlighting the importance of extremely defined tissue lysates for protein profiling...
  30. ncbi Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry
    Julia Diegmann
    Core Unit Chip Application CUCA, Institute of Human Genetics and Anthropology, Friedrich Schiller University, 07740 Jena, Germany
    Eur J Cancer 41:1794-801. 2005
    ..With our combined approach we were able to identify CD70 as a new marker for RCC, which may be useful in the future for improved immunohistochemical diagnosis...
  31. ncbi Clonal origin of multifocal renal cell carcinoma as determined by microsatellite analysis
    Kerstin Junker
    Department of Urology, Institute of Pathology, Friedrich Schiller University, Jena, Germany
    J Urol 168:2632-6. 2002
    ..It remains largely unknown whether small satellite tumors show malignant features and whether they are metastases from the primary tumor. Therefore, we determined the clonality of multifocal tumors by molecular genetic analysis...
  32. ncbi Genetic profile of bone metastases in renal cell carcinoma
    Kerstin Junker
    Department of Urology, Friedrich Schiller University, Lessingstr 1, 07743 Jena, Germany
    Eur Urol 45:320-4. 2004
    ..The aim of this study was to define specific genetic alterations which are common in bone metastases in renal cancer patients...
  33. ncbi Genetic subtyping of renal cell carcinoma by comparative genomic hybridization
    Kerstin Junker
    Department of Urology, Friedrich Schiller University, 07743 Jena, Germany
    Recent Results Cancer Res 162:169-75. 2003
    ..The definition of genetic alterations seems helpful for a tumor typing especially when morphology is equivocal. Therefore, genetic analyses represent a powerful diagnostic and prognostic tool for RCC...
  34. ncbi A possible noninvasive method for the detection of bladder cancer in patients: microsatellite analysis of free DNA in urine and blood
    M Utting
    Department of Urology, Friedrich Schiller University, Jena, Germany
    Ann N Y Acad Sci 945:31-5. 2001
    ..However, new ways for the sensitive DNA isolation of body fluids are needed...
  35. ncbi Transforming growth factor beta 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma
    U Junker
    Institute of Clincial Immunology, Friedrich Schiller University Jena, Germany
    Cytokine 8:794-8. 1996
    ..It is concluded that elevated latent TGF-beta 1 is common in RCC, is at least partially produced by the tumour and might be a cause for local immunosuppressive effects within the tumour...
  36. ncbi PAR-1- and PAR-3-type thrombin receptor expression in primary cultures of human renal cell carcinoma cells
    R Kaufmann
    Department of General and Visceral Surgery, Medical Faculty at the Friedrich Schiller University Jena, D 07740 Jena, Germany
    Int J Oncol 20:177-80. 2002
    ..On the outer cell membrane, clustering of PAR-1 and PAR-3 molecules was partly observed. This is the first study demonstrating presence of both PAR-1 and PAR-3 in human carcinoma cells...
  37. ncbi Meizothrombin, an intermediate of prothrombin cleavage potently activates renal carcinoma cells by interaction with PAR-type thrombin receptors
    R Kaufmann
    Research Laboratory, Department of General and Visceral Surgery, Institute of Immunology, Medical Faculty at the Friedrich Schiller University Jena, Research Center Lobeda, Germany
    Oncol Rep 10:493-6. 2003
    ..Our results demonstrate rMT as a potent activator of human RCC cells suggesting a function of not only thrombin but also of this catalytically active thrombin precursor enzyme in human renal cell carcinoma...
  38. doi Improvement of histopathological classification of adrenal gland tumors by genetic differentiation
    Torsten Gruschwitz
    Department of Urology, University Medical Center, Lessingstrasse 1, 07743, Jena, Germany
    World J Urol 28:329-34. 2010
    ..The purpose of this study was to define specific genetic alterations differentiating between adenomas and carcinomas...
  39. doi B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder?
    Petra Richter
    Institute of Pathology, University Hospital Jena, Ziegelmühlenweg 1, 07743 Jena, Germany
    J Cancer Res Clin Oncol 135:1351-8. 2009
    ..The study was aimed at investigating urinary concentrations of tenascin-C splicing domains for their value as tumour surveillance markers...
  40. ncbi Identification of tumor entities of renal cell carcinoma using interphase fluorescence in situ hybridization
    Jimsgene Sanjmyatav
    Department of Urology, Friedrich Schiller University, Jena, Germany
    J Urol 174:731-5. 2005
    ..We developed a rapid interphase fluorescence in situ hybridization (FISH) test to differentiate renal cell carcinoma (RCC) based on known genetic alterations and verified the suitability of this test for practical use...
  41. doi Multi-colour FISH on preoperative renal tumour biopsies to confirm the diagnosis of uncertain renal masses
    Aliaksei Chyhrai
    Department of Urology, University Hospitals, Friedrich Schiller University Jena, Lessingstrasse 1, 07743 Jena, Germany
    World J Urol 28:269-74. 2010
    ..In our study, we evaluated the benefit of multi-colour interphase fluorescence in situ hybridization (M-FISH) on fine-needle core biopsies in uncertain renal masses...
  42. doi Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer
    Astrid Enkelmann
    Laboratory of Molecular Biology, Department of Urology, Jena University Hospital, 07740, Jena, Germany
    J Cancer Res Clin Oncol 137:751-9. 2011
    ..Aims of the present study are the isolation of TAF from primary urinary bladder tumour specimens and the proteomic and epigenetic characterisation...
  43. doi Immunochemotherapy-associated protein patterns in tumour tissue and serum of patients with metastatic renal cell carcinoma
    Martina Walter
    Department of Urology, University Hospitals Jena, Lessingstraße 1, 07743 Jena, Germany
    Arch Physiol Biochem 116:197-207. 2010
    ..It is crucial to recognize these patients for individual treatment...
  44. ncbi Analysis of genetic alterations in normal bladder urothelium
    Kerstin Junker
    Department of Urology, Friedrich Schiller University, Jena, Germany
    Urology 62:1134-8. 2003
    ....
  45. ncbi TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples
    Regine Dahse
    Klinikum der FSU Jena, Institut fur Humangenetik, D 07740 Jena, Germany
    Int J Oncol 20:107-15. 2002
    ..We conclude that TP53 genotyping as a non-invasive diagnostic tool in outpatient samples is of limited value for clinical practice...
  46. ncbi The accuracy of 250 fine needle biopsies of renal tumors
    Heiko Wunderlich
    Department of Urology and the Institute of Pathology WH, Friedrich Schiller University, Jena, Germany
    J Urol 174:44-6. 2005
    ..In this study we evaluated the accuracy of and the impact on tumor management of core biopsy for histopathological evaluation of small solid renal masses...
  47. ncbi Gain in chromosome 8q correlates with early progression in hormonal treated prostate cancer
    Thomas Steiner
    Department of Urology, Friedrich Schiller University, Jena, Germany
    Eur Urol 41:167-71. 2002
    ..Clinical studies evaluating genetic aberrations of prior therapy biopsies in correlation with progression data in patients receiving hormone therapy for prostate cancer have not been performed until now...
  48. ncbi Ultrasound-guided biopsy of homogenous solid renal masses
    Olaf Reichelt
    Department of Urology, Friedrich Schiller University, Jena, Germany
    Eur Urol 52:1421-6. 2007
    ..We evaluated the reliability of sonographic criteria in selecting solid renal masses for percutaneous fine-needle biopsy...
  49. ncbi Prediction of renal allograft rejection by urinary protein analysis using ProteinChip Arrays (surface-enhanced laser desorption/ionization time-of-flight mass spectrometry)
    Olaf Reichelt
    Department of Urology, Friedrich Schiller University, Jena, Germany
    Urology 67:472-5. 2006
    ..To develop a noninvasive method for the detection of renal transplant rejection using ProteinChip Arrays (surface-enhanced laser desorption/ionization time-of-flight mass spectrometry)...
  50. ncbi Comparative study of renal cell carcinoma by CGH, multicolor-FISH and conventional cytogenic banding analysis
    Jimsgene Sanjmyatav
    Department of Urology, FSU Jena, Lessingstrasse 1, 07743 Jena, Germany
    Oncol Rep 14:1183-7. 2005
    ..The combined analysis of RCC by different methods allowed a more accurate characterization of the complex karyotypes of tumor tissue, and offered a comprehensive description of given tumors...
  51. doi Immunohistochemical marker panel differentiates between the three most common subtypes of renal cell carcinoma independent from histomorphologic criteria
    B Walter
    Department of Urology, Friedrich Alexander University, Erlangen, Germany
    Virchows Arch 460:343-52. 2012
    ..Further improvement is needed for consistent detection of clear cell RCC and for dependably ruling out all three main subtypes as well as identification of rare variants and benign lesions like oncocytoma...
  52. ncbi Comparative transcriptional and functional profiling of clear cell and papillary renal cell carcinoma
    Julia Diegmann
    Core Unit Chip Application CUCA, Institute of Human Genetics and Anthropology, Friedrich Schiller University, 07740 Jena, Germany
    Int J Mol Med 18:395-403. 2006
    ..The combination of transcriptional and functional profiling revealed potential target molecules for novel therapy strategies that must be studied in more detail...
  53. ncbi [Correlation of FGFR3 mutations and chromosomal alterations in bladder cancer]
    Kerstin Junker
    Klinik für Urologie, Universitat, Jena
    Verh Dtsch Ges Pathol 90:151-8. 2006
    ..The low malignant potential of these tumors is underlined by a low number of chromosomal alterations per tumor. Therefore, FGFR3 could represent a prognostic marker of chromosomally stable tumors with low malignant potential...
  54. pmc Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes
    Julia Diegmann
    Core Unit Chip Application, Institute of Human Genetics and Anthropology, Friedrich Schiller University, Jena 07740, Germany
    Neoplasia 8:933-8. 2006
    ..Apoptosis mediated by exposure to the CD70 secreted by tumor cells may contribute to the failure of RCC patients to develop an effective lymphocyte-mediated antitumor response...
  55. doi Genetic variants of the copy number polymorphic beta-defensin locus are associated with sporadic prostate cancer
    Klaus Huse
    Genome Analysis, Leibniz Institute for Age Research, Fritz Lipmann Institute, Jena, Germany
    Tumour Biol 29:83-92. 2008
    ..This structural variation considerably hampers genetic studies. In a new approach considering both sequence as well as copy number variations we aimed to compare the defensin locus at 8p23 in prostate cancer patients and controls...
  56. doi Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability
    Christian Eichelberg
    Department of Urology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Eur Urol 55:851-63. 2009
    ..However, progression and treatment response are still not sufficiently predictable. Molecular markers could help to refine individual risk stratification and treatment planning, although they have not yet become clinically routine...
  57. ncbi Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer
    Michael Utting
    Department of Urology, Friedrich Schiller University Jena, 07743 Jena, Germany
    Clin Cancer Res 8:35-40. 2002
    ..The detection of tumors by microsatellite analysis of free DNA offers a possibility to establish a minimally invasive method for the detection of bladder cancer...
  58. ncbi The serine proteinase thrombin promotes migration of human renal carcinoma cells by a PKA-dependent mechanism
    R Kaufmann
    Department of General and Visceral Surgery, Medical Faculty at the Friedrich Schiller University Jena, Bachstr 18, 07740 Jena, Germany
    Cancer Lett 180:183-90. 2002
    ..We concluded, that thrombin acts as a regulator on human A-498 renal carcinoma cell migration including PKA...
  59. doi IIICS de novo glycosylated fibronectin as a marker for invasiveness in urothelial carcinoma of the urinary bladder (UBC)
    Petra Richter
    Institute of Pathology, Friedrich Schiller University, Jena, Germany
    J Cancer Res Clin Oncol 134:1059-65. 2008
    ..Until now there are no data available regarding the source and distribution of oncf Fn in UBC and its value for the assessment of invasiveness...
  60. pmc Metanephric adenoma of the kidney: a clinicopathological and molecular study of two cases
    Maximilian Burger
    Department of Urology, University of Regensburg, Regensburg, Germany
    J Clin Pathol 60:832-3. 2007
  61. ncbi [Urothelial neoplasms in individuals younger than 20 years show very few genetic alterations and have a favourable clinical outcome]
    Johannes Giedl
    Institut fur Pathologie, Universitat Regensburg, Regensburg
    Verh Dtsch Ges Pathol 90:253-63. 2006
    ..Urothelial neoplasms in patients 19 years or younger are rare, with conflicting data regarding clinical outcome and no molecular data available...
  62. ncbi Molecular evidence for progression of nephrogenic metaplasia of the urinary bladder to clear cell adenocarcinoma
    Arndt Hartmann
    Institute of Pathology, University of Regensburg, D 93042, Germany
    Hum Pathol 37:117-20. 2006
    ..Results of molecular studies, particularly comparative genomic hybridization analysis, suggest clonal evolution of nephrogenic metaplasia to clear cell adenocarcinoma in this case...
  63. ncbi P53 mutations as an identification marker for the clonal origin of bladder tumors and its recurrences
    Regine Dahse
    HELIOS Clinic Erfurt, Institute of Pathology, D 99089 Erfurt, Germany
    Oncol Rep 10:2033-7. 2003
    ..For further implications concerning clonality of recurrent bladder tumors, p53 status should be combined with a broader range of markers such as CGH and LOH pattern...
  64. ncbi Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine at UCLA, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90025, USA
    BJU Int 100:21-5. 2007
    ..To present a multicentre experience and the largest cohort to date of nonmetastatic (N0M0) synchronous bilateral renal cell carcinoma (RCC), as because it is rare the single-institutional experience is limited...
  65. ncbi Frequent microsatellite instability in sporadic tumors of the upper urinary tract
    Arndt Hartmann
    Institute of Pathology, University of Regensburg, 93042 Regensburg, Germany
    Cancer Res 62:6796-802. 2002
    ....
  66. ncbi PAR-type thrombin receptors in renal carcinoma cells: PAR1-mediated EGFR activation promotes cell migration
    Sebastian Bergmann
    Department of General, Friedrich Schiller University Jena, D 07747 Jena, Germany
    Oncol Rep 15:889-93. 2006
    ..Further, our results underline the importance of PAR1-mediated pathways in kidney cancer cells and suggest that the thrombin/PAR1 system mediating EGFR transactivation may play a role in the progression of this tumor entity...
  67. ncbi Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90025, USA
    J Urol 177:2081-6; discussion 2086-7. 2007
    ..We evaluated the prognosis, risk factors and relevance of the primary-free interval in a large cohort with metachronous bilateral renal cell carcinoma...